Forvis Mazars Wealth Advisors LLC Sells 39 Shares of Eli Lilly and Company $LLY

Forvis Mazars Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 0.1% during the second quarter, HoldingsChannel.com reports. The firm owned 43,509 shares of the company’s stock after selling 39 shares during the quarter. Eli Lilly and Company makes up approximately 0.7% of Forvis Mazars Wealth Advisors LLC’s holdings, making the stock its 22nd largest holding. Forvis Mazars Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $33,917,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Precedent Wealth Partners LLC boosted its stake in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after purchasing an additional 429 shares in the last quarter. Family CFO Inc bought a new position in Eli Lilly and Company in the 2nd quarter worth about $54,000. Duquesne Family Office LLC lifted its stake in Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC bought a new position in Eli Lilly and Company during the 1st quarter valued at about $570,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. HSBC upped their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $939.12.

Insider Buying and Selling

In other news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $803.53 on Friday. The firm’s 50 day moving average price is $753.09 and its 200-day moving average price is $765.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $760.51 billion, a PE ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the business earned $3.92 EPS. The business’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.